Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted ...

Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...

A Tapestry high school senior never imagined his senior year would be interrupted by a cancer diagnosis. Dakarai Jackson Jr.

Obe-cel is under regulatory review in both the EU and the U.K., and the Company expects to receive notification of approval status from the Medicines and Healthcare products Regulatory Agency (MHRA) ...

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were taking cholesterol-lowering statin medications at the start of their cancer treatment had a 61% lower risk ...

Allogene Therapeutics, Inc.’s ALLO share price has surged by 5.28%, which has investors questioning if this is right time to ...

Now, Kaufman, a 20-year-old sophomore baseball player and business finance major at Roanoke College, is facing his toughest ...

As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...

BREVARD COUNTY, FLORIDA – Sunday, April 27, 2025, at 1 p.m., the American Legion Post 200, 105 Ocean Blvd., Satellite Beach, ...

More than five years have passed since the arrival in Italy of the first anti -cancer gene therapy, the Car-t ...

After 3.5 years of follow-up, there was a 98% rate of minimal residual disease, and 9 patients were still in complete remission.